You have 9 free searches left this month | for more free features.

Anti-CD19 Chimeric Antigen Receptor

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

Not yet recruiting
  • Follicular Lymphoma
  • Axicabtagene Ciloleucel
  • +5 more
  • (no location specified)
Sep 21, 2023

Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • anti-CD19 CAR NK cells (KN5501)
  • Shanghai, China
    Changhai Hospital
Aug 25, 2023

Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,

Not yet recruiting
  • Idiopathic Inflammatory Myopathies
  • +3 more
  • (no location specified)
Nov 21, 2023

Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • +2 more
  • PACE CART19
  • (no location specified)
Mar 9, 2022

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

B-cell Non Hodgkin Lymphoma Trial in Seoul (AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
  • Seoul, Korea, Republic of
    Asan Medical Center
May 24, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

CD19-ALL, CD19-LNH Trial in Roma (CD19-CAR T cell)

Active, not recruiting
  • CD19-ALL
  • CD19-LNH
  • CD19-CAR T cell
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19

Recruiting
  • Lymphoblastic Leukemia
  • +5 more
  • Anti-CD19 CAR T-cells
  • Singapore, Singapore
  • +1 more
Dec 4, 2022

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) Trial in Zhengzhou, Hangzhou (CD19-UCART)

Recruiting
  • Acute Lymphoblastic Leukemia (ALL)
  • Non Hodgkin Lymphoma (NHL)
  • CD19-UCART
  • Zhengzhou, Henan, China
  • +1 more
Apr 2, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the

Completed
  • Primary Mediastinal B-cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 29, 2021

Systemic Lupus Erythematosus (SLE) Trial (BRL-301)

Not yet recruiting
  • Systemic Lupus Erythematosus (SLE)
  • BRL-301
  • (no location specified)
Aug 13, 2023

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma Trial in Dongguan (Drugs and Anti-CD19-CAR transduced T

Completed
  • Acute Lymphocytic Leukemia
  • +2 more
  • Drugs and Anti-CD19-CAR transduced T cells
  • Dongguan, Guangdong, China
    Department of Hematology, Dongguan People's Hospital
Mar 16, 2021

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022